Clinical Trial Update: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating SHR2150 (TLR7 agonist) in combination with chemotherapy plus PD-1 or CD47 antibody for unresectable/metastatic solid tumors (Phase 1/Phase 2)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• CD47 antibody (CD47 antibody)
• PD-1 antibody (PD-1 inhibitor)
• SHR2150 (SHR2150)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN